49th week of 2013 patent applcation highlights part 46 |
Patent application number | Title | Published |
20130323172 | MOLECULAR PROBES FOR MULTIMODALITY IMAGING OF ANIONIC MEMBRANE SURFACES - Embodiments provide dual modality probes for imaging phosphatidylserine (PS) exposure and other anionic membrane surfaces. In various embodiments, the probes were constructed by utilizing a) the high selectivity of synthetic zinc (II) dipicolylamine coordination complexes (Zn-DPA) for targeting externalized PS which over-expresses in apoptotic and necrotic cells, b) a near-infrared (NIR) dye for optical imaging, and c) a widely used clinically approved radionuclide for PET (or SPECT) imaging. A variety of linking elements were incorporated into the probes between the Zn-DPA and radionuclide motif to modulate the pharmacokinetics. The in vitro and in vivo data of radiolabeled dipicolylamine probes demonstrated their utilities for imaging PS exposure with multiple imaging modalities. | 2013-12-05 |
20130323173 | ANTIBODIES TO TUMOR ENDOTHELIAL MARKER 8 - The present invention is directed to particular antibodies and fragments thereof that find use in the detection, prevention and treatment of diseases and disorders associated with abnormal angiogenesis. In particular, these antibodies detect tumor endothelial marker 8 (TEM8) in its native and cell-surface expressed form. Also disclosed are improved methods for producing monoclonal antibodies, as well as pharmaceutical compositions and kits. | 2013-12-05 |
20130323174 | METHODS OF DETECTING PANCREOBILIARY DUCTAL LEAKS - The present invention is directed to a method for identifying ductal leaks during pancreobiliary surgery in a human patient. The invention comprises the steps of: administering to a human patient undergoing pancreobiliary surgery an effective amount of a pharmaceutical composition comprising secretin and a pharmaceutically acceptable carrier; and observing the patient during the surgery for the presence of pancreobiliary ductal leaks. | 2013-12-05 |
20130323175 | USE OF 31P NMR SPECTROSCOPY OF WHOLE HEART ENERGETICS FOR DETECTION OF DRUG-INDUCED CARDIOTOXICITY - Disclosed are methods of determining cardiac toxicity of a compound of interest, wherein a heart or cardiac cell of a mammal may be contacted a compound of interest and peak levels of one or more indicators of cardiac energetics after administration of the compound may be detected using | 2013-12-05 |
20130323176 | GALECTIN-9-SECRETING CELL, AND PRODUCTION METHOD AND USE OF THE SAME - The object of the present invention is to provide a cell that can exhibit physiological activity based on galectin-9, a method for producing the cell, and use of the cell. In order to achieve the above object, the cell of the present invention contains galectin-9, and the galectin-9 is expressed on a cell surface. | 2013-12-05 |
20130323177 | TUMOR-TARGETING GAS-GENERATING NANOPARTICLE, METHOD FOR PREPARING THE SAME, AND TUMOR-TARGETING NANOPARTICLE FOR DRUG DELIVERY USING THE SAME - A tumor-targeting gas-generating nanoparticle, a method for preparing same and a tumor-targeting nanoparticle for drug delivery using same relate to a tumor-targeting gas-generating nanoparticle including a polycarbonate core and a amphiphilic coat, a method for preparing same and a tumor-targeting nanoparticle for drug delivery using same. Since a tumor-targeting gas-generating nanoparticle according to the present disclosure is accumulated in the tumor tissue in large quantity and generates strong ultrasound wave signals, it can be usefully used as a contrast agent for ultrasonic imaging. | 2013-12-05 |
20130323178 | INDOCYANINE GREEN-CONTAINING PARTICLE AND CONTRAST AGENT FOR PHOTOACOUSTIC IMAGING HAVING THE PARTICLE - Provided is the following indocyanine green (ICG)-containing particle to be used as, for example, a contrast agent for fluorescent imaging or photoacoustic imaging. The leakage of ICG from the particle in a serum is prevented and hence the particle can stably retain ICG. According to a particle characterized by having an aggregate of indocyanine green and a phospholipid, the leakage of ICG from the particle in a serum or the like is prevented and hence ICG can be stably retained in the particle. | 2013-12-05 |
20130323179 | NANOCRYSTALS, COMPOSITIONS, AND METHODS THAT AID PARTICLE TRANSPORT IN MUCUS - Nanocrystals, compositions, and methods that aid particle transport in mucus are provided. In some embodiments, the compositions and methods involve making mucus-penetrating particles (MPP) without any polymeric carriers, or with minimal use of polymeric carriers. The compositions and methods may include, in some embodiments, modifying the surface coatings of particles formed of pharmaceutical agents that have a low water solubility. Such methods and compositions can be used to achieve efficient transport of particles of pharmaceutical agents though mucus barriers in the body for a wide spectrum of applications, including drug delivery, imaging, and diagnostic applications. In certain embodiments, a pharmaceutical composition including such particles is well-suited for administration routes involving the particles passing through a mucosal barrier. | 2013-12-05 |
20130323180 | COMPOSITION OF A FIRST NON-LABELED MONOCLONAL ANTIBODY BINDING TO A TUMOR ANTIGEN AND A NON-CROSS REACTIVE SECOND MONOCLONAL ANTIBODY LABELED WITH A NIR FLUORESCENCE LABEL - This invention relates to a composition of a non-labeled monoclonal antibody binding to a tumor antigen and a second monoclonal antibody labeled with a NIR fluorescence label, binding to the same tumor antigen, wherein the first and second antibody exhibit no cross reactivity. The composition can be used for the treatment of patients suffering of solid tumors which are associated with an overexpression of such a tumor antigen. The invention further relates to a the co-administration of said first and second antibody as wells as to a method of acquiring a NIR fluorescence images of such tumors or the patients suffering from such tumors during the treatment of said patient with such composition. | 2013-12-05 |
20130323181 | STABILIZED FORMULATIONS CONTAINING IODINATED CONTRAST AGENTS AND CYCLODEXTRINS - The invention encompasses compositions containing an iodinated contrast agent and a substituted cyclodextrin wherein the cyclodextrin stabilizes the contrast agent against degradation by ultraviolet or visible light exposure. | 2013-12-05 |
20130323182 | METHOD OF PREPARING IRON OXIDE NANOPARTICLES COATED WITH HYDROPHILIC MATERIAL, AND MAGNETIC RESONANCE IMAGING CONTRAST AGENT USING THE SAME - The present invention relates to a method of preparing biocompatible iron oxide nanoparticles by coating iron oxide nanoparticles having improved magnetism via annealing treatment using salt particles with a hydrophilic material and to a magnetic resonance imaging (MRI) contrast agent including the iron oxide nanoparticles prepared thereby. Among hydrophilic materials, carboxymethyl dextran (CM-dextran) is the most efficient in terms of stabilizing the annealed iron oxide nanoparticles and exhibiting contrast effects. | 2013-12-05 |
20130323183 | ABSORBENT DRESSINGS WITH PAINKILLING ACTIVITY - The invention discloses pharmaceutical compositions in the form of a dusting powder or dry spray, possessing a high absorbent capacity, painkilling activity and wound-healing action, which compositions consist of croscarmellose sodium, a non-steroidal anti-inflammatory drug (NSAID) and hyaluronic acid, and optionally also contain other pharmacologically active substances and/or excipients. The compositions disclosed herein are suitable for use in the treatment of skin lesions wherein the presence of exudate limits wound healing and causes pain; they are therefore particularly suitable for chronic ulcerous skin lesions of various origins and burns. | 2013-12-05 |
20130323184 | Method Of Providing Fast Relief To A User Of A Nicotine Chewing Gum - The invention relates to a method of relieving nicotine craving comprising the steps of providing at least one chewing gum comprising tobacco alkaloid to a user, providing relief of nicotine craving to said user by transferring of tobacco alkaloid from the chewing gum to the human body of said user by chewing of said chewing gum, said chewing of said chewing gum comprising a chewing process involving a transfer of tobacco alkaloid from said chewing gum above a threshold transfer rate in the period of about ½ minute to about 2½ minutes from initiation of said chewing process. | 2013-12-05 |
20130323185 | METHODS OF ANALYZING PLAQUE - The invention provides a method of measuring ammonia and/or calcium in a sample of dental plaque, comprising obtaining the sample of plaque and measuring ammonium and calcium ions using capillary electrophoresis, together with methods of diagnosis, treatment and screening based on evaluation of plaque. | 2013-12-05 |
20130323186 | Dentifrice Composition - A dentifrice, such as toothpaste, containing chitosan or pharmaceutically acceptable acid addition salt thereof with fluoride ions, for use against erosive tooth demineralization, and kits containing chitosan or pharmaceutically acceptable acid addition salt thereof with fluoride ions, wherein one of the two active agents is comprised in a dentifrice, are described. The dentifrice in the form of toothpaste may furthermore comprise dissolved tin, in particular stannous ions. Toothpastes containing chitosan or pharmaceutically acceptable acid addition salt thereof with fluoride ions are tested in the treatment or prevention of erosive tooth demineralisation caused by citric acid. | 2013-12-05 |
20130323187 | SYNTHETIC PEPTIDES FOR USE AS INHIBITORS OF NEUROTRANSMITTER SECRETION AND AS INDUCERS OF CELLULAR RELAXATION - The present invention describes material and methods related to synthetic peptides which block the secretion of neurotransmitters and induce muscle relaxation, and use of said peptides as inhibitors of neurotransmitter secretion and muscle contraction, and as inducers of muscle relaxation. | 2013-12-05 |
20130323188 | Water Soluble Fullerene Formulations and Methods of Use Thereof - The present invention provides water soluble fullerene formulations and methods of use thereof. | 2013-12-05 |
20130323189 | ANTIFUNGAL NAIL COAT AND METHOD OF USE - Antifungal nail coat compositions containing an allylamine, an N,N-di(C | 2013-12-05 |
20130323190 | COMPOSITION GENERATING HYDROGEN - There is provided an external-use composition that is incorporated with a hydrogen storing metal alloy keeping the hydrogen and generating the hydrogen, and that has the antioxidant effect, anti-inflammation effect and antiallergic effect. | 2013-12-05 |
20130323191 | COSMETIC PRODUCTS FOR REDUCING HAIR APPEARANCE - A cosmetic product for reducing the appearance of hair. The cosmetic product includes a composition made with at least one film forming polymer present in an amount sufficient to reduce the appearance of hair on a skin surface, and a dermatologically acceptable carrier. The product also includes indicia that communicates to a user that the composition is to be applied along the direction of hair growth on the area of skin where hair appearance reduction is desired. | 2013-12-05 |
20130323192 | BASE MAKEUP COSMETIC AND METHOD FOR PRODUCING THE SAME - Provided are a method of producing a base makeup cosmetic, which includes mixing a solvent and a cosmetic base material including a red composite powder having a composite structure in which red pigment selected from the group consisting of lithol rubine B and lithol rubine BCA is intercalated into an inorganic substance, and filling the slurry into a container and then removing the solvent, as well as a base makeup cosmetic. | 2013-12-05 |
20130323193 | OIL-SOLUBLE DEODORANT COMPOSITION AND METHOD FOR DEODORIZING AMMONIA ODOR AND AMINE ODOR - The present invention provides an oil-soluble deodorant composition that is highly safe, efficienctly eliminates odors of ammonia, amines and the like and is free of an irritant odor and the like. The present invention relates to an oil-soluble deodorant composition containing at least one of a dimer acids and a trimer acids as an active ingredient. | 2013-12-05 |
20130323194 | METHOD OF ELIMINATING CAT URINE ODOR - A method of eliminating cat urine odor. A CO2 generating mixture of carboxylic acid and a base is placed into a container and cat litter that is comprised of an absorbent material is placed over the top. During the deodorizing process of the cat urine, carbon dioxide is generated to enhance the deodorizing effect of the absorbent material. | 2013-12-05 |
20130323195 | HYDROGEL FIBRES AND FIBROUS STRUCTURES - A plurality of fibers or one-dimensional, two-dimensional, or three-dimensional fibrous structures are provided, having fibers from a first raw fiber material. The first raw fiber material contains unsubstituted or partially substituted polyvinyl alcohol and/or unsubstituted or partially substituted polyvinyl alcohol copolymer. The fibers can be crosslinked by tempering the fibers or fibrous structures, with the result that the fibers or the fibrous structure are configured to be gel, in particular hydrogel, fibers or fibrous structures and have excellent stability. | 2013-12-05 |
20130323196 | METHOD FOR MOBILIZING STEM AND/OR PROGENITOR CELLS - The present disclosure relates to methods for mobilizing stem and/or progenitor cells which are VLA-4 positive to the peripheral blood of a subject or from a tissue. The method comprises administering to the subject or tissue an effective amount of an antisense compound to VLA-4. | 2013-12-05 |
20130323197 | IFG-1 DEPENDENT MODULATION OF VSELS - Characteristics of the VSELs stem cell population of a mammal are correlated with aging, including VSEL number, imprinting status of genetic loci, and expression of markers of pluripotent stem cells. The present invention provides VSEL-based methods and compositions for determining the biological age of a mammal. | 2013-12-05 |
20130323198 | Use of AMG 900 for the Treatment of Cancer - The present invention relates to methods of using AMG 900, a small molecule pan aurora kinase inhibitor, for the treatment of cancer, including solid tumors, hematologically derived tumors and the like. The invention further provides pharmaceutical compositions, dosage ranges and treatment regimens for administering AMG 900 to treat cancer. | 2013-12-05 |
20130323199 | COLLAGEN MATERIAL AND METHOD FOR PRODUCING COLLAGEN MATERIAL - A collagen material is characterized in being constituted of collagen gel fragments. Furthermore, the collagen gel fragments may have an orientation. A method for producing a collagen material is characterized in comprising a step for preparing collagen gel fragments, a step for arranging the collagen gel fragments in a desired shape, and a step for drying the collagen gel fragments arranged in the desired shape. Moreover, in one embodiment of the method for producing a collagen material a step may include imparting an orientation to the collagen gel fragments. | 2013-12-05 |
20130323200 | GELSOLIN ENRICHMENT OF BLOOD SAMPLES USING GOLD PARTICLES - In the method for producing at least one therapeutically effective protein or a protein mixture in a container, the container is filled with a body fluid and gold particles and incubated, and in this process the therapeutically effective protein is formed in the body fluid. | 2013-12-05 |
20130323201 | Combination Treatments and Compositions for Wound Healing - Viral VEGF and viral anti-inflammatory cytokine compositions, methods of treatment using them, and kits containing them for use in the promotion and/or improvement of wound healing and/or tissue repair, and for anti-scarring, anti-inflammatory, anti-fibrosis and anti-adhesion indications. | 2013-12-05 |
20130323202 | METHODS OF TREATING OCULAR AND OTHER DISEASES WITH SYN-134R POLYPEPTIDE - Disclosed herein TPV1 is a method of treating ocular and systemic conditions by administering IL-10 and TPV134R polypeptides. | 2013-12-05 |
20130323203 | INHIBITORS OF FLAVIVIRIDAE VIRUSES - Provided are compounds of Formula I: | 2013-12-05 |
20130323204 | Multimeric Complexes with Improved in Vivo Stability, Pharmacokinetics and Efficacy - The present invention concerns multimeric complexes based on antibody fusion proteins comprising an AD moiety attached to the C-terminal end of each antibody light chain. The complexes further comprise effector moities attached to DDD moieties. Two copies of the DDD moiety form a dimer that binds to the AD moiety. The complexes may be trimers, pentamers, hexamers or other multimers. The effector moieties may be selected from a second antibody or antigen-binding fragment thereof, a cytokine, an interferon, a toxin, an antigen, a xenoantigen, a hapten, a protamine, a hormone, an enzyme, a ligand-binding protein, a pro-apoptotic agent and an anti-angiogenic agent. Surprisingly, attachment of the AD moiety to the C-terminal end of the antibody light chain results in improved pharmacokinetics and in vivo stability and efficacy, compared to homologous complexes wherein the AD moiety is attached to the antibody heavy chain. | 2013-12-05 |
20130323205 | ONCOLYTIC ADENOVIRAL VECTORS AND METHODS AND USES RELATED THERETO - The present invention relates to the fields of life sciences and medicine. Specifically, the invention relates to cancer therapies. More specifically, the present invention relates to oncolytic adenoviral vectors and cells and pharmaceutical compositions comprising said vectors. The present invention also relates to said vectors for treating cancer in a subject and a method of treating cancer in a subject. Furthermore, the present invention relates to methods of producing CD40L in a cell and increasing tumor specific immune response and apoptosis in a subject, as well to uses of the oncolytic adenoviral vector of the invention for producing CD40L in a cell and increasing tumor specific immune response and apoptosis, while decreasing tumor-associated immunosuppression, in a subject. | 2013-12-05 |
20130323206 | GENE DELIVERY SYSTEM HAVING ENHANCED TUMOR-SPECIFIC EXPRESSION, AND RECOMBINANT GENE EXPRESSION REGULATING SEQUENCE - The present invention relates to a gene expression regulating sequence consisting of a combination of HRE, E2F and TERT, and to a gene delivery system having significantly improved selective tumor cell cytotoxicity using same, and more particularly, to a recombinant adenovirus. In addition, the present invention relates to a pharmaceutical antitumor composition comprising the recombinant adenovirus. The replication of the recombinant adenovirus of the present invention is tumor-specifically regulated by the novel gene expression regulating sequence of the present invention, thus enabling the recombinant adenovirus of the present invention to exhibit improved selective tumor cell cytotoxicity or apoptotic potential, and exhibit remarkably improved antitumor effects particularly in hypoxic conditions. In addition, the specific expression of the recombinant adenovirus in tumor cells may increase in vivo stability, and thus may induce greatly improved antitumor effects. | 2013-12-05 |
20130323207 | PRODUCTS AND METHODS FOR DELIVERY OF POLYNUCLEOTIDES BY ADENO-ASSOCIATED VIRUS FOR LYSOSOMAL STORAGE DISORDERS - The present invention relates to methods and materials useful for systemically delivering polynucleotides across the blood brain barrier using adeno-associated virus as a vector. For example, the present invention relates to methods and materials useful for systemically delivering α-N-acetylglucosamidinase polynucleotides to the central and peripheral nervous systems, as well as the somatic system. Use of these methods and materials is indicated, for example, for treatment of the lysosomal storage disorder mucopolysaccharidosis IIIB. As another example, the present invention relates to methods and materials useful for systemically delivering N-sulphoglucosamine sulfphohydrolase polynucleotides to the central and peripheral nervous systems, as well as the somatic system. Use of this second type of methods and materials is indicated, for example, for treatment of the lysosomal storage disorder mucopolysaccharidosis IIIA. | 2013-12-05 |
20130323208 | MYCOBACTERIUM BRUMAE CELL WALL EXTRACTS THAT CAN BE USED IN THERAPY OF SUPERFICIAL BLADDER CANCER - Invention is using | 2013-12-05 |
20130323209 | NOVEL BACTERIOPHAGE AND ITS USE FOR PREVENTING PROLIFERATION OF PATHOGENIC BACTERIA - The present invention relates to a novel phage, which is newly isolated and identified, a composition for inhibiting growth of bacteria or killing thereof comprising the same as an active ingredient, and the present invention can be diversely used as a composition for preventing or treating bacterial infectious diseases, a composition for treating ballast water, an antibiotic, an antiseptic, a feed additive and the like. | 2013-12-05 |
20130323210 | INFECTIOUS SCHMALLENBERG VIRUS FROM CLONED CDNAS AND USES THEREOF - The present invention belongs to the field of animal health and relates to a nucleic acid sequence which comprises the complete genome of an infectious Schmallenberg virus (SBV) useful for studying viremia and diseases caused by SBV in ruminants, and in the development of vaccines, therapeutics and diagnostics for the prophylaxis, treatment and diagnosis of viremia and diseases caused by SBV. | 2013-12-05 |
20130323211 | SHORT RNA MOLECULES - The present invention provides a short RNA capable of upregulating MafA expression in a human cell, wherein said short RNA includes a first strand which is 19 to 25 nucleotides in length and comprises the sequence AUCUGUACUGGAUGAGCGG or UUUCCCGCAGGAGAUUGAC. Also provided are uses thereof, particular medical uses, and induced cells and uses thereof. | 2013-12-05 |
20130323212 | Treatment for Chronic Myocardial Infarct - A method of treating chronic post-myocardial infarction including helical needle transendocardial delivery of autologous bone marrow (ABM) mononuclear cells around regions of hypo or akinesia in chronic post-myocardial infarction (MI) patients. The treatment is safe and improves ejection fraction (EF). | 2013-12-05 |
20130323213 | ADHERENT CELLS FROM ADIPOSE OR PLACENTA TISSUES AND USE THEREOF IN THERAPY - A method of treating ischemia in a subject in need thereof is disclosed. The method comprising administering to the subject a therapeutically effective amount of adherent cells of a tissue selected from the group consisting of a placenta and an adipose tissue, thereby treating the ischemia in the subject. A method of treating a medical condition requiring connective tissue regeneration and/or repair is also disclosed. | 2013-12-05 |
20130323214 | CHIMERIC CD27 RECEPTORS FOR REDIRECTING T CELLS TO CD70-POSITIVE MALIGNANCIES - The present invention concerns methods and compositions related to T cells redirected against CD70 for the immunotherapy of CD70-positive malignancies. In aspects of the invention, T cells that are CD70-specific are employed. In particular aspects, there are T cells expressing a novel molecule that comprises the full-length CD70 receptor (CD27) fused to the zeta signaling domain of the T-cell receptor complex. Such T cells recognized CD70-positive tumor cells and have cytolytic activity against CD70-positive cancer cells. | 2013-12-05 |
20130323215 | Tumour Cytotoxic Agent and Methods Thereof - The present invention discloses a novel antitumour agent which provides an antitumour activity based on metabolites with reduced side effects. Moreover, the antitumour agent is prepared starting with a highly safe bacterium used in food production, which is a probiotic lactic acid bacterium. | 2013-12-05 |
20130323216 | SYNBIOTIC MIXTURE - This invention relates to a preparation comprising N-acetyl-lactosamine and/or an oligosaccharide containing N-acetyl-lactosamine and a probiotic | 2013-12-05 |
20130323217 | COMPOSITIONS AND METHODS FOR THE CONTROLLED REPOPULATION OF GRAM-NEGATIVE BACTERIA IN THE COLON - The present invention relates to a method for the controlled repopulation of the colonic bacterial flora. | 2013-12-05 |
20130323218 | Methods of Selecting and Using Therapeutic and Prophylactic Probiotic Cultures to Reduce Bacterial Pathogen Loads - Methods are provided for selecting a bacterium capable of reducing pathogenic bacterial colonization of the intestinal tract in a subject comprising selecting the bacterium capable of migrating at least 0.75 cm from the point of inoculation on motility agar after incubation for 24 hours at 37° C. or capable of migrating from the point of inoculation to a diameter of at least 1.5 cm based on the farthest colonies from the point of inoculation on motility agar after incubation for 24 hours at 37° C. Bacteria selected using the method and compositions comprising these bacteria are also provided. | 2013-12-05 |
20130323219 | COMPOSITION COMPRISING A COMBINATION OF AT LEAST ONE PROTEOLYTIC ENZYME AND AT LEAST ONE LIPOLYTIC ENZYME, FOR USE IN PREVENTING TRIGLYCERIDE SYNTHESIS - The present invention relates to a composition comprising a combination of at least one proteolytic enzyme, such as subtilisin, and at least one lipolytic enzyme, for use in preventing triglyceride synthesis, advantageously by degrading 2-monoacylglycerol in the intestine. The invention also has as an object such a composition for use as a drug, cosmetic agent, medical device, dietary composition, dietary supplement or nutraceutical, notably for use in preventing or treating obesity, atherosclerosis, type 2 diabetes or for use in preventing or reducing excess weight. | 2013-12-05 |
20130323220 | TAL-Tet1 Fusion Proteins and Methods of Use Thereof - Fusion proteins comprising a DNA binding domain, e.g., a TAL effector repeat array or zinc finger, and a catalytic domain comprising a sequence that catalyzes hydroxylation of methylated cytosines in DNA, and methods of use thereof. | 2013-12-05 |
20130323221 | PLANT LECTINS AS CARRIERS OF ASSOCIATED DRUG SUBSTANCES INTO ANIMAL AND HUMAN CELLS - The current invention involves the use of protein lectins produced by plants including the non-toxic carbohydrate binding subunits (B subunits) of plant “AB toxins” (PTB lectins) as delivery vehicles for mobilizing associated drug substances for delivery to animal and human cells. The resulting protein fusions or conjugates retain lectin carbohydrate specificity for binding to cells and cellular trafficking activity so as to deliver an associated drug compound to the site of disease manifestation. One embodiment of this invention concerns the ability of ricin toxin B subunit, as a model PTB lectin, to deliver enzyme replacement therapeutic drugs to cells of several organs of the body including the brain and central nervous system, eyes, ears, lungs, bone, heart, kidney, liver, and spleen for treating lysosomal diseases. | 2013-12-05 |
20130323222 | HUMAN TISSUE KALLIKREIN 1 GLYCOSYLATION ISOFORMS - Provided are preparations of tissue kallikrein-1 (KLK1) glycoforms having a defined number of oligosaccharide units per KLK1 molecule. Also provided are mixtures of such glycoforms, pharmaceutical compositions containing such glycoforms or mixtures thereof, methods of obtaining the rhKLK1 glycoforms, and therapeutic uses thereof | 2013-12-05 |
20130323223 | METHODS OF TREATING CELIAC DISEASE - Described herein are compositions which include digestive enzymes and which are formulated to reduce one or more symptoms of celiac disease or a related disorder. Also described herein is a method for treating a subject with celiac disease or a related disorder using digestive enzymes and their derivatives to alleviate the symptoms of celiac disease or a related disorder. The method comprises administering to the individual an effective amount of digestive enzymes that are either naturally or recombinantly derived, or their derivatives, in an amount effective to reduce one or more symptoms of celiac disease or a related disorder. | 2013-12-05 |
20130323224 | USE OF MYCOBACTERIUM SMEGMATIS TREHALOSE DIMYCOLATE HYDROLASE - Methods are disclosed herein for treating an infection with a | 2013-12-05 |
20130323225 | Broccoli Based Nutritional Supplements - A nutritional supplement is provided containing two broccoli based components that are combined and, when ingested, react in the intestines to provide sulforaphane. Processes for producing the broccoli components of the nutritional supplement are also provided. The broccoli components are treated separately using supercritical fluid extraction to remove oils. The temperature and pressure of the supercritical extraction processes are controlled to provide broccoli components having the desired properties for the nutritional supplement. | 2013-12-05 |
20130323226 | Compositions and Methods for Altering Tissue Specificity and Improving AAV9-Mediated Gene Transfer - A method of altering the targeting and/or cellular uptake efficiency of an adeno-associated virus (AAV) viral vector having a capsid containing an AAV9 cell surface binding domain is described. The method involves modifying a clade F cell surface receptor which comprises a glycan having a terminal sialic acid residue and a penultimate β-galactose residue. The modification may involve retargeting the vector by temporarily functionally ablate AAV9 binding in a subset of cells, thereby redirecting the vector to another subset of cells. Alternatively, the modification may involve increasing cellular update efficiency by treating the cells with a neuraminidase to expose cell surface β-galactose. Also provided are compositions containing the AAV9 vector and a neuraminidase. Also provided is a method for purifying AAV9 using β-galactose linked to solid support. Also provided are mutant vectors which have been modified to alter their targeting specificity, including mutant AAV9 in which the galactose binding domain is mutated and AAV in which an AAV9 galactose binding domain is engineered. | 2013-12-05 |
20130323227 | PHARMACEUTICAL COMPOSITIONS OF TENECTEPLASE - Pharmaceutical compositions of tenecteplase that are safe and effective in the treatment of acute ischemic stroke compared with the known compositions are disclosed. The compositions of the invention are invented based on a series of testing trials on the different amounts of the TNK and isolating specific amount that is optimally suitable in terms of desired effects of TNK in the treatment of acute ischemic stroke. | 2013-12-05 |
20130323228 | CLEANSING AND ANTI-ACNE COMPOSITION - Disclosed is a cleansing composition and methods for its use capable of treating acne comprising an anti-acne agent comprising benzoyl peroxide, a combination of cleansing agents comprising disodium laureth sulfosuccinate and sodium C14-16 olefin sulfonate, and a combination of skin active ingredients comprising | 2013-12-05 |
20130323229 | METABOLIC THERAPY FOR OXIDATIVE STRESS IN THE BRAIN THROUGH TARGETED NEURONAL CATABOLISM OF N-ACETYL-ASPARTIC ACID - The present invention provides a novel method of treatment for treating brain disorders that manifest oxidative stress by providing targeted populations of neurons with the ability to catabolize the acetylated amino acid derivative, N-acetylaspatic acid (NAA) and further supply extraphysiological levels of ATP to neurons via the targeted expression of the NAA catabolic enzyme aspartoacylase (ASPA) in neurons and astrocytes. | 2013-12-05 |
20130323230 | TREATMENT OF MYELOSUPPRESSION - Methods are presented for attenuating myelosuppressive side effects of treatment regimens, promoting thrombopoiesis and neutrophil production, and increasing efficacy of treatment regimens, by administering PF4-interacting heparinoids. | 2013-12-05 |
20130323231 | TREATMENT AND PROGNOSIS OF SOLID TUMOUR CANCERS - The invention is based on the finding that the human RPT4 protein/gene can function as a therapeutic target for solid tumour type cancers, especially solid tumours of the colon, and that reducing the abundance of RPT4 in tumour cells causes a significant increase in cancer cell death, and potently decreases the survival and proliferation of cancer cells in tumour growth assays (FIGS. | 2013-12-05 |
20130323232 | METHODS FOR THE IDENTIFICATION AND TREATMENT OF PATIENTS SENSITIVE TO ANTI IGF-1R INHBITION THERAPY - Disclosed herein are methods of stratifying a patient population into an IGF-1R inhibitor responder or resistant population comprising assaying a sample of cells derived from a patient to determine if a cell from the patient sample is sensitive to treatment with an IGF-1R inhibitor and selecting a patient for treatment with an IGF-1R inhibitor if the cells from the patient are determined to be sensitive. The determination is based upon either the expression levels of wild type LKB1 in the patient sample wherein a low level of expression of the protein or the gene encoding the biomarker protein is predictive of a favorable outcome to an IGF-1R targeted therapy or detecting the presence of a loss of function mutant LKB1 in the sample, wherein presence of the mutant is predictive of a favorable outcome. The presence of the mutant may be accompanied by determining the expression level of IGF-1R in the same sample, wherein a concomitant increase in the level of expression of IGF-1R in addition to detecting the presence of the mutant protein also predicts a favorable outcome to an IGF-1R targeted therapy. Methods of treating a patient are also provided. | 2013-12-05 |
20130323233 | MATERIALS AND METHODS FOR IMPROVED IMMUNOGLYCOPROTEINS - Immunoglycoproteins, including antibodies, with improved ADCC and altered glycosylation patterns are provided. Also provided are cell culturing methods and media for producing such immunoglycoproteins, and therapeutic uses of such immunoglycoproteins. | 2013-12-05 |
20130323234 | MUTANT ANTIBODIES AND CONJUGATION THEREOF - The present invention relates to a polypeptide comprising 7 β-strands A, B, C, D, E, F, and G sequentially connected together by connecting chains of amino acids, and a first α-helix sequentially located on the EF chain between β-strands E and F, wherein the β-strands are arranged so as to form a first β-sheet comprising β-strands A, B, D, and E, and a second β-sheet comprising β-strands C, F and G, said first and second β-sheets being covalently bonded together so as to form a first Ig domain; wherein the EF chain between β-strands E and F comprises the sequence X | 2013-12-05 |
20130323235 | Soluble heavy-chain only antibodies - The present invention provides a high affinity, antigen-specific, soluble heavy chain-only antibody which: lacks hallmark camelid-related amino acid substitutions and has FR2 substitutions which are not found in antibodies which comprise heavy and light chain; shows increased net hydrophobicity within CDR1 and an increased number of charged amino acids present in CDR3; and comprises one or more amino acid substitutions within the framework β-pleated sheet leading to increased net hydrophobicity within FR1 and increased number of charged amino acids present in FR3. Also provided are VH domains having the same properties, gene segments for their production, methods for their production, transgenic animals and uses of the antibody of the VH domains in therapy. | 2013-12-05 |
20130323236 | Antibodies of the Class IGG4 - The present invention provides an antibody of the class IgG4 comprising at least one heavy chain which comprises a C | 2013-12-05 |
20130323237 | ORGANIC COMPOUNDS - The present invention relates to human thymic stromal lymphopoietin (hTSLP) antibodies and especially those which neutralize hTSLP activity. It further relates to methods for using anti-hTSLP antibody molecules in diagnosis or treatment of hTSLP related disorders, such as asthma, atopic dermatitis, allergic rhinitis, fibrosis, inflammatory bowel disease and Hodgkin's lymphoma. | 2013-12-05 |
20130323238 | ANTAGONISTS OF IL-6 TO RAISE ALBUMIN AND/OR LOWER CRIP - The present invention is directed to therapeutic methods using IL-6 antagonists such as antibodies and fragments thereof having binding specificity for IL-6 to improve survivability or quality of life of a patient in need thereof. In preferred embodiments these patients will comprise those exhibiting (or at risk of developing) an elevated serum C-reactive protein level or a reduced serum albumin level prior to treatment. In another preferred embodiment, the patient's Glasgow Prognostic Score will be increased and survivability will preferably be improved. | 2013-12-05 |
20130323239 | MODULATION OF PILR RECEPTORS TO TREAT SEPSIS - The present invention provides methods of using agonists and antagonists of PILRα and PILRβ, respectively, to treat immune mediated sepsis. Also provided are methods of prophylactically treating with agonists and antagonists of PILRα and PILRβ, respectively, to prevent the development of sepsis. | 2013-12-05 |
20130323240 | HUMANIZED ANTIBODIES AGAINST LIGHT AND USES THEREOF - The present invention is directed to antigen-binding polypeptides, or variants or derivatives thereof which specifically bind the LIGHT polypeptide. The invention is also directed to methods of making and using such antibodies specifically in the treatment or diagnosis of immune, inflammatory and malignant diseases or conditions (e.g. inflammatory bowel disease; Crohn's disease, ulcerative colitis, multiple sclerosis, rheumatoid arthritis and transplantation). | 2013-12-05 |
20130323241 | TREATMENT OF ANGIOGENESIS DISORDERS - This invention concerns pathological angiogenesis and cancer, related treatment methods, and related compositions. Also disclosed are related diagnosis kits and methods. | 2013-12-05 |
20130323242 | COMPOSITIONS COMPRISING AN ANTI-PDGF APTAMER AND A VEGF ANTAGONIST - The present invention is directed to compositions comprising an anti-PDGF aptamer and a VEGF antagonist. In certain embodiments, the compositions of the invention are useful for treating or preventing an ophthalmological disease. | 2013-12-05 |
20130323243 | FILOVIRUS FUSION PROTEINS AND THEIR USES - This invention provides fusion proteins comprising a Filovirus glycoprotein segment and an immunoglobulin polypeptide segment. The fusion proteins are useful in immunogenic compositions to protect against infections by Filoviruses, such as Ebola virus, in both humans and non-human animals. The fusion proteins are also useful in diagnostic assays to detect Filovirus infections. | 2013-12-05 |
20130323244 | COMPOSITIONS COMPRISING ALKALINE PHOSPHATASE AND/OR NATRIURETIC PEPTIDE AND METHODS OF USE THEREOF - The present invention provides methods, compositions, and kits for the treatment of neurocutaneous syndromes, such as neurofibromatosis type I; disorders associated with overactivation of FGFR3, such as achondroplasia; bone or cartilage disorders; or vascular smooth muscle disorders; or for the elongation of bone. In some embodiments, the present invention provides polypeptides having an alkaline phosphatase peptide fused to an Fc domain of an immunoglobulin or a natriuretic peptide fused to an Fc domain of an immunoglobulin. Such polypeptides can be administered to subjects, e.g., subcutaneously, to treat a neurocutaneous syndrome, a disorder associated with overactivation of FGFR3, a bone or cartilage disorder, or a vascular smooth muscle disorder, or to elongate bone. The invention also features nucleic acid molecules encoding such polypeptides and the use of the nucleic acid molecules for treating neurocutaneous syndromes, disorders associated with overactivation of FGFR3, bone or cartilage disorders, or vascular smooth muscle disorders, or for elongating bone. | 2013-12-05 |
20130323245 | CHEMOKINE-IMMUNOGLOBULIN FUSION POLYPEPTIDES, COMPOSITIONS, METHOD OF MAKING AND USE THEREOF - This application is directed to chemokine-immunoglobulin fusion polypeptides and chemokine-polymer conjugates. The fusion polypeptides and conjugates can be used for treating chemokine receptor-mediated disorders and modulating inflammation, inflammatory cell motility, cancer cell motility, or cancer cell survival. | 2013-12-05 |
20130323246 | USE OF MDL-1 ANTAGONISTS TO TREAT SPONDYLARTHROPATHY - The invention provides methods for treating spondylarthropathy with antagonists of MDL-1 alone or in combination with IL-23 antagonists. | 2013-12-05 |
20130323247 | TREATMENT OF ACUTE LYMPHOBLASTIC LEUKEMIA - The present invention relates to a method for the treatment, amelioration or elimination of acute lymphoblastic leukemia (ALL), the method comprising the administration of a pharmaceutical composition comprising a CD19xCD3 bispecific single chain antibody construct to an adult patient in the need thereof. | 2013-12-05 |
20130323248 | Antigen Binding Proteins that Bind DLL-4 - There is disclosed compositions and methods relating to or derived from anti-DLL-4 antibodies. More specifically, there is disclosed fully human antibodies that bind DLL-4, DLL-4-binding fragments and derivatives of such antibodies, and DLL-4-binding polypeptides comprising such fragments. Further still, there is disclosed nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having DLL-4 related disorders or conditions, including various inflammatory disorders and various cancers. | 2013-12-05 |
20130323249 | Antigen Binding Proteins that Bind PD-L1 - There is disclosed compositions and methods relating to or derived from anti-PD-L1 antibodies. More specifically, there is disclosed fully human antibodies that bind PD-L1, PD-L1-binding fragments and derivatives of such antibodies, and PD-L1-binding polypeptides comprising such fragments. Further still, there is disclosed nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having PD-L1 related disorders or conditions, including various inflammatory disorders and various cancers. | 2013-12-05 |
20130323250 | ANTI-CLTA4, ANTI-GLUT2 PROTEIN FOR THE TREATMENT OF TYPE 1 DIABETES - The disclosure relates to a protein composed of a first polypeptide or polypeptide domain having a first specific binding activity for Cytotoxic T-lymphocyte Antigen 4 (CTLA-4) expressed on a T-cell cell surface and a second specific binding activity for Glucose Transporter 2 (GLUT2) or an extracellular ectodomain thereof expressed on a pancreatic β-cell surface, wherein binding of the first polypeptide or polypeptide domain to CTLA-4 induces a CTLA-4 specific agonist response in the T-cell, and binding of the second polypeptide or polypeptide domain to GLUT2 or an ectodomain thereof does not inhibit GLUT2 glucose transporter function, wherein said agonist response in the T-cell induces a response that reduces immunoreactivity against pancreatic β-cells. | 2013-12-05 |
20130323251 | USE OF IL-23 AND IL-17 ANTAGONISTS TO TREAT AUTOIMMUNE OCULAR INFLAMMATORY DISEASE - Novel methods and drug products for treating autoimmune ocular inflammatory disease are disclosed, which involve administration of agents that antagonize one or both of IL-17 and IL-23 activity. | 2013-12-05 |
20130323252 | Molecules And Methods For Modulating TMEM16A Activities - The present invention provides molecules that bind to TMEM16A (“TMEM16A binding molecules”), particularly human or humanized antibodies and antibody drug conjugates that bind to human TMEM16A and modulate its functions. Epitopes of TMEM16A and molecules that bind these epitopes are also provided herein. | 2013-12-05 |
20130323253 | XYXIN FRAGMENT BIOMARKER FOR DIAGNOSIS OF COLON CANCER - The present invention relates to the field of the diagnosis of large intestine/colon diseases. More particularly, the present invention provides a method for differential diagnosis of colorectal cancer from a non-malignant disease of the large intestine/colon, and from a healthy large intestine/colon. The invention also relates to treatment of colorectal cancer. | 2013-12-05 |
20130323254 | THERAPEUTIC ANTI-TIRC7 ANTIBODIES FOR USE IN IMMUNE RELATED AND OTHER DISEASES - Provided are specific antibodies against T-cell immune response cDNA7 (TIRC7) costimulatory molecule, which are capable of inhibiting proliferation of peripheral blood mononuclear cells (PBMCs). In particular, high affinity monoclonal and chimeric anti-TIRC7 antibodies are described. Compositions comprising such antibodies and their use for the treatment of immune diseases are provided. | 2013-12-05 |
20130323255 | SERUM MG53 AS A DIAGNOSTIC MARKER FOR TISSUE INJURY - Disclosed herein are compositions and methods for measuring the level of MG53 found in a biological fluid as a biomarker for a disease or disorder, e.g., tissue damage, exercise capacity or a muscle-related disease or disorder. In addition, the invention relates to targeting the native MG53 found in the blood as a therapeutic approach. | 2013-12-05 |
20130323256 | S. AGALACTIAE ANTIGENS I + II - The present invention discloses isolated nucleic acid molecules encoding a hyperimmune serum reactive antigen or a fragment thereof as well as hyperimmune serum reactive antigens or fragments thereof from | 2013-12-05 |
20130323257 | ANTIBODIES THAT BIND THE GLUTAMATE LIGAND BINDING REGION OF NOTCH3 - Isolated antibodies that specifically binds to an extracellular conserved ligand binding region of a human Notch receptor and inhibits growth of a tumor are described. Also described are methods of treating cancer, the method comprising administering an anti-Notch antibody in an amount effective to inhibit tumor growth. | 2013-12-05 |
20130323258 | COMPOSITIONS AND METHODS FOR TREATING CARDIVASCULAR DISEASE - The invention pertains to methods of treating cardiovascular disease by modulating inflammatory and immunoregulatory responses associated with such pathological conditions. Embodiments of the invention provide methods for the treatment of cardiovascular disease comprising administering an effective amount of one or more IL-17 antagonists, IL-18 antagonists, 4-1BB antagonists, CD30 antagonists, OX40 antagonists and/or CD39 alone or in any combination. | 2013-12-05 |
20130323259 | IL-21 LIGANDS - The present invention relates to IL-21 ligands binding to a discontinuous epitope on the surface of the IL-21 molecule as well as use thereof. | 2013-12-05 |
20130323260 | STABILIZED FORMULATIONS CONTAINING ANTI-DLL4 ANTIBODIES - The present invention provides pharmaceutical formulations comprising an antibody that specifically binds to human delta-like ligand 4 (Dll4). The formulations may contain, in addition to an anti-Dll4 antibody, a phosphate buffer, an organic cosolvent, a disaccharide, and a salt. The pharmaceutical formulations of the present invention exhibit a substantial degree of antibody stability after storage for several months and after being subjected to thermal and other physical stress | 2013-12-05 |
20130323261 | PURIFIED ANTIBODY COMPOSITION - The invention provides a method for producing a host cell protein-(HCP) reduced antibody preparation from a mixture comprising an antibody and at least one HCP, comprising an ion exchange separation step wherein the mixture is subjected to a first ion exchange material, such that the HCP-reduced antibody preparation is obtained. | 2013-12-05 |
20130323262 | METHODS AND MATERIALS FOR TREATING INFLAMMATORY CONDITIONS - Methods and kits for treating inflammatory conditions are described that include modulating kallikrein 6 protease activity. | 2013-12-05 |
20130323263 | SPARC ANGIOGENIC DOMAIN AND METHODS OF USE - The invention provides compositions and methods which exploit the discovery of the SPARC carboxy angiogenic domain. | 2013-12-05 |
20130323264 | DIAGNOSTIC AND THERAPEUTIC USES OF MOESIN FRAGMENTS - The present application provides compositions and methods for modulating the activity and quantity of platelets and preventing and treating disorders or diseases associated with abnormal activity and quantity of platelets. | 2013-12-05 |
20130323265 | METHODS FOR TREATING CANCER WITH DLL4 ANTAGONISTS - The present invention provides methods for treating cancer. More particularly, the invention provides methods for treating cancer comprising administrating doses of a DLL4 antagonist. | 2013-12-05 |
20130323266 | METHODS FOR TREATING CANCER WITH NOTCH2/3 ANTIBODIES - The present invention provides methods for treating cancer. More particularly, the invention provides methods for treating cancer comprising administrating doses of a Notch2/3 antibody. | 2013-12-05 |
20130323267 | HIGHLY CONCENTRATED ANTI-CD40 ANTIBODY PHARMACEUTICAL PREPARATION - The present invention relates to a highly concentrated solution preparation of antagonistic anti-CD40 antibody, in which occurrence of turbidity or insoluble foreign matter attributed to antibodies is suppressed to a level equivalent to that of the conventional low-concentration lyophilized preparation. | 2013-12-05 |
20130323268 | CYTOTOXIC AGENTS COMPRISING NEW ANSAMITOCIN DERIVATIVES - New ansamitocin derivatives bearing a linking group are disclosed. Also disclosed are methods for the synthesis of these new ansamitocin derivatives and methods for their linkage to cell-binding agents. The ansamitocin derivative-cell-binding agent conjugates are useful as therapeutic agents, which are delivered specifically to target cells and are cytotoxic. These conjugates display vastly improved therapeutic efficacy in animal tumor models compared to the previously described agents. | 2013-12-05 |
20130323269 | METHODS AND COMPOSITIONS FOR DELIVERY OF ACTIVE AGENTS - A lipid particle can include a cationic lipid. The cationic lipid can include one or more hydrophobic tails, which can include one or more sites of unsaturation. The sites of unsaturation can include cycloalkyl groups, e.g., cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl groups. The lipid particle is suitable for delivering an active agent. | 2013-12-05 |
20130323270 | CYCLOSPORINE EMULSION - The present invention relates to a cyclosporine emulsion containing: i) a cyclosporine ii) a natural oil (long chain triglyceride) iii) a phosphatidylcholine, iv) glycerol, v) a pharmaceutically tolerable alkali salt of a free fatty acid, vi) a medium chain triglyceride-oil vii) optionally, hydrochloric acid or sodium hydroxide for pH adjustment viii) water. | 2013-12-05 |
20130323271 | NITRIC OXIDE DONOR NEPRILYSIN INHIBITORS - In one aspect, the invention relates to compounds having the formula: | 2013-12-05 |